Sponsors

Ajinomoto Bio-Pharma Services is a fully integrated contract development and manufacturing organization with sites in Belgium, United States, Japan, and India, providing comprehensive development, cGMP manufacturing, and aseptic fill finish services for small and large molecule APIs and intermediates. Ajinomoto Bio-Pharma Services offers a broad range of innovative platforms and capabilities for pre-clinical and pilot programs to commercial quantities, including Corynex® protein expression technology, AJIPHASE® oligonucleotide synthesis, ADC, HPAPI, biocatalysis, continuous flow manufacturing and more.

TA Instruments, a division of Waters Corporation, is a world leader in manufacturing innovative and reliable instruments that contribute to groundbreaking discoveries in medicine, materials science, and other scientific areas devoted to improving our world. TA Instruments recognizes that large molecule biochemists require simple, sensitive, and reproducible assays to elucidate biomolecular structures and functions. We offer a comprehensive set of 21 CFR Part 11 compliant solutions that are essential for ensuring desired product quality and guaranteeing safety and efficacy in the biopharmaceutical industry. Our technical support group is located in 24 countries across the globe and are available by phone or email to help you achieve your research goals.

Abzena is the leading end-to-end bioconjugate, ADC, and complex biologics CDMO + CRO. From discovery through commercial launch, we support customers with fully integrated programs or individual services designed to de-risk and streamline the development of new treatments for patients in need. With the ability to tailor its strategy and customer experience to each project, Abzena develops and implements innovative solutions that enable biotech and biopharma companies to realize the full potential of their molecule and move medicines forward faster. The company has research, development, and cGMP facilities across locations in San Diego, CA, Bristol, PA, and Cambridge, UK.

Alloy Therapeutics accelerates the drug discovery process by providing access to best-in-class foundational drug discovery platforms, services, and company creation capabilities. Alloy Therapeutics has developed novel strains for fully human antibody discovery and created innovative technology to support a multitude of modalities that can help to quickly identify candidates. Leveraging our world class scientists, Alloy therapeutics platforms and services enables you to build a more robust antibody-based therapeutic pipeline.

DelSiTech is the leader in using and developing biodegradable, amorphous silica (SiO2) matrix and sol-gel encapsulation technologies in drug delivery. The applicability of Silica Matrix technology is widespread. Silica matrix technology enables parenteral drug delivery routes such as subcutaneous, intramuscular, intraocular, and topical delivery, among many others. In addition, the therapeutic indications that the company is working on include metabolic diseases, musculoskeletal diseases, infectious diseases, oncology, and pain. DelSiTech's Silica Matrix technology can deliver a wide range of therapeutic agents, from poorly soluble small molecules to large biologics, over an extended period. The Silica Matrix is fully biodegradable, ensuring true controlled release and can enable stabilization of drug substances. With Silica Matrix technology, stable release profiles can be customized to last from days to a year, with minimal initial burst release.

MaxCyte is a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support innovative, cell-based research. MaxCyte builds best-in-class technology designed to facilitate complex engineering of a wide variety of cells and to drive the rapidly expanding cell therapy market forward. For over 20 years, MaxCyte has been a leader in developing transfection workflows and ventures beyond today’s processes to innovate tomorrow’s solutions. MaxCyte is headquartered in Rockville, Maryland’s I-270 Biotech Corridor. To learn more, please visit www.maxcyte.com.

PipeBio is an integrated cloud platform for no-code, end-to-end bioinformatic workflows for therapeutic antibody and biologics discovery. Used by both wet-lab scientists and bioinformaticians, the PipeBio platform features a powerful set of tools for sequence analysis and advanced visualizations. PipeBio allows creation of automated and standardized sequence analysis pipelines.

As part of the Danaher family of global life science and technology innovators, SCIEX continue to pioneer robust solutions in capillary electrophoresis and mass spectrometry. Our unique technologies enable scientists to achieve comprehensive characterization and sensitive quantification of various modalities, including protein therapeutics, cell & gene therapies, in simple and complex biological matrices. But we don’t just develop products. It is what we do together with our customers that sets us apart. That’s why thousands of life science experts around the world choose SCIEX to get the answers they can trust better inform critical decisions. Decisions that positively impact lives. We proudly stand behind our tagline: The Power of Precision.

Sphere Fluidics is the Cambridge (UK)-based microfluidics tools company with a range of novel cell encapsulation products for single-cell analysis and isolation. The Sphere Fluidics proprietary picodroplet microfluidic technology platform is designed specifically for single-cell screening and isolation, allowing users to encapsulate and analyze single cells within a droplet while maintaining viability. Flagship product Cyto-Mine® provides an integrated system with the ability to select, manipulate, analyze, and isolate cells, through an easy to use and intuitive interface that can automatically screen up to 40 million cells in a matter of hours. This unrivaled throughput aids in the acceleration of biopharmaceutical discovery and development, cell therapy, and synthetic biology workflows, easing the journey of discovery in labs globally.

Cradle performs ML-guided lead optimization, helping R&D teams hit their protein engineering goals 1.5-12x faster. Our intuitive software platform enables scientists to easily work with state-of-the-art generative machine learning and offers different levels of control depending on the user's ML expertise. Cradle's models can optimize multiple properties across a range of modalities, and grow more powerful with every round of experimental data you upload. Models trained on your data are entirely private to you and you retain full IP over the sequences generated. Cradle only charges a flat annual subscription fee for access to its protein engineering platform. We are proud to partner with leaders including Novo Nordisk, Johnson & Johnson, Grifols and Twist Biosciences.

We are providing a unique platform technology named PUREfrex®, which is a fully reconstituted (or rebuilt) cell-free protein expression system. It's easy to customize the system for various applications at the molecular level. It has been widely used not only for the expression of difficult-to-express proteins, including therapeutic biologics, but also as a platform for high-throughput expression or in vitro display, which works synergistically with the AI/ML platform. We are exploring the potential of cell-free technologies in biologics.

GenScript Biotech Corporation (HK.1548) is a world leader in technologies and services for life science R&D and manufacturing. Built upon its solid DNA synthesis technology, the company comprises four major business units: a life-science services and products business unit, a biologics contract development and manufacturing organization (CDMO) business unit, an industrial synthetic products business unit, and an integrated global cell therapy company. GenScript accelerates scientific discovery and therapeutic breakthroughs with its customers. Since its founding in New Jersey, USA in 2002, GenScript has expanded its operations to serve more than 200,000 customers across 100 countries with a dedicated team of 6,900 employees. As of December 31, 2023, 87,700 peer-reviewed journal articles worldwide had cited GenScript ’s services and products. Guided by its mission to make people and nature healthier through biotechnology, GenScript strives to become the most trustworthy biotech company in the world. For more information, please visit GenScript Biotech's official website https://www.genscript.com

NOF CORPORATION, the leading commercial supplier of drug delivery products through R&D to commercial scale, provides activated PEGs for protein modification, single molecular PEGs for ADCs, Polysorbate 80 for formulation of biological medicines, PEG lipids and ionizable lipids for lipid nanoparticle (LNP) formulations. NOF's lipid nanoparticle platform for nucleic acid delivery composed of COASOMEⓇ SS Series, novel biodegradable ionizable lipid, demonstrates superior endosomal escape and provides high protein expression with extremely low systemic toxicity. The platform can be applied to gene delivery, gene editing, nucleic acid vaccine and in vitro transfection. It is capable of encapsulating pDNA, siRNA and mRNA, and delivering these to various organs and tissues. NOF LNP platform is becoming adopted in clinical planning by NOF collaborators.

Here’s the deal. We’re all about helping biologics and gene therapy researchers break free from tools that just don’t cut it. Unleashing problem-tackling solutions that make a huge difference in the real science they do every day. That’s our mantra, our promise and we own it.

Founded in 2012 and certified to ISO 9001:2015, Biointron is a CRO specializing in antibody discovery, expression, and optimization services for biotech and pharmaceutical companies. Biointron holds a leading position in the antibody expression service industry. From gene sequence to purified antibodies, our production only takes 2 weeks. We have delivered tens of thousands of recombinant antibodies for more than 1,800 biotech and pharma companies worldwide. Contact us: +1(732)790-8340, or info@biointron.com. Visit our website: www.biointron.com

Evitria AG is a Swiss-based global leader in transient expression and purification services of antibodies and proteins. We provide expert guidance in antibody, bispecific and multispecific development with HT screening production, optimized purification approaches, and novel technologies to explore. Our fourteen-year history with >130,000 successful protein production runs highlights a rapid and reliable platform, and we are excited to share this with the community in-person at Biologics US 2024.

FORMULATRIX® collaborates with researchers to simplify the preparation and analysis of proteins and nucleic acids by designing solutions without boundaries and bringing cutting-edge technology to the life science industry. We supply software and laboratory automation solutions to the top pharmaceutical companies and leading academic research institutions working in a variety of genomics and proteomics applications. We are committed to researchers, labs, and to the scientific discoveries that will improve the lives of generations to come.

Hamilton’s automated liquid handling systems empower labs worldwide but are just one part of our overall lab capabilities. Our technologies work together to create customized solutions for your workflows. Innovation for a better world.

Nicoya is a pioneering company at the forefront of democratizing scientific exploration through groundbreaking advancements in microfluidics and nanotechnology. Committed to making cutting-edge label-free surface plasmon resonance (SPR) technology accessible to scientists across disciplines, Nicoya specializes in miniaturizing biomolecular binding analysis, with the aim to simplify experiments by automating user operation, reducing sample sizes by more than 100-fold, and eliminating bulky and complex instrumentation, ultimately providing researchers with cost-effective and easy-to-use tools. At Nicoya, our commitment to making technology more accessible drives us to empower scientists globally, fostering a new era of exploration and innovation.

Quantum-Si, The Protein Sequencing Company™, has a mission to make protein sequencing and analysis available to all scientists so that every lab, everywhere can better understand the role of proteins in cell biology and disease and use this knowledge to transform the world we live in. QSI brings the groundbreaking power of single-molecule proteomics with the first-to-market Next-Generation Protein Sequencer™, Platinum® and a straightforward workflow, space-saving benchtop instrument, and the power to precisely detect protein variants and modifications.

Selvita Group has broad expertise and track record in oncology, inflammation, fibrosis, anti-infectives, respiratory diseases and CNS. The company offers drug discovery support at every stage of the early discovery phase up to the preclinical development. Selvita specializes in a variety of drug discovery processes from in silico drug design and synthesis of a target-focused library, SAR and ADME-driven lead optimization and toxicity prediction, followed by complex preclinical in vitro and in vivo pharmacology, structural biology, all tailored to the customer’s needs.

SGS is the world’s leading inspection, verification, testing and certification company. With more than 90,000 employees, SGS operates a network of over 1,500 offices and laboratories around the world. The Life Science division serves pharmaceutical, biopharmaceutical, and medical device companies along the entire drug development pathway. With over 35 years’ experience as a global contract service organization, SGS provides integrated (bio)pharmaceutical development and testing solutions including clinical research, pharmaceutical development, biologics characterization, biosafety, and quality control testing for small and large molecules, raw materials, containers and finished products. SGS Vitrology provides a comprehensive range of biosafety services such as: virology, cell and molecular biology as well as microbiology and electron microscopy. Health Authorities, including the US FDA and the EMA, require companies to undergo safety testing demonstrating that cell banks, viral banks, raw materials, bulk harvests, and batches of clinical drug are free of bacteria, fungi, mycoplasma, viruses, and other potential contaminants. SGS Vitrology helps clients by ensuring product safety in satisfying these regulatory requirements. Our GLP/GMP facility is MHRA certified, and US FDA audited.